Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Mysthera Therapeutics Develops First-in-Class Autoimmune Disease Therapies

Mysthera Therapeutics has pioneered groundbreaking oral treatments for complex autoimmune diseases. 

They focus on PIM kinases, which play a vital role in multiple immune cell types, like B and T cells, triggering excessive inflammation. Elevated PIM kinase levels may also contribute to the formation of tertiary lymphoid structures (TLS), linked to disease severity and progression.

The innovative approach uniquely targets the communication between these cells, disrupting the harmful formation of TLS associated with more severe disease cases. 

Leveraging deep expertise in PIM kinase and immunology, Mysthera is taking a highly distinctive approach to combat complex autoimmune diseases, potentially bringing life-changing treatments to patients worldwide.

Despite recent advancements and new treatment options, autoimmune diseases continue to affect over 23 million people in the US alone, with significant unmet needs due to poor response rates and safety concerns associated with existing medications.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024